GSA Capital Partners LLP bought a new stake in Bausch Health Companies Inc (NYSE:BHC) during the third quarter, Holdings Channel reports. The fund bought 52,800 shares of the company’s stock, valued at approximately $1,355,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of BHC. Point View Wealth Management Inc. acquired a new position in shares of Bausch Health Companies in the second quarter valued at about $1,132,000. Private Management Group Inc. acquired a new position in shares of Bausch Health Companies in the second quarter valued at about $28,474,000. Van ECK Associates Corp acquired a new position in shares of Bausch Health Companies in the second quarter valued at about $11,494,000. Marshall Wace LLP acquired a new position in shares of Bausch Health Companies in the second quarter valued at about $2,974,000. Finally, NEXT Financial Group Inc acquired a new position in shares of Bausch Health Companies in the third quarter valued at about $101,000. 50.09% of the stock is currently owned by institutional investors and hedge funds.
Bausch Health Companies stock opened at $23.66 on Friday. The stock has a market cap of $8.48 billion, a P/E ratio of 6.14, a P/E/G ratio of 0.32 and a beta of -0.28. Bausch Health Companies Inc has a 52 week low of $14.44 and a 52 week high of $28.45. The company has a current ratio of 1.14, a quick ratio of 0.91 and a debt-to-equity ratio of 7.55.
In other Bausch Health Companies news, CFO Paul Herendeen acquired 10,000 shares of the company’s stock in a transaction on Friday, September 14th. The shares were bought at an average cost of $22.61 per share, with a total value of $226,100.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph C. Papa acquired 30,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was acquired at an average cost of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 165,000 shares of company stock worth $3,890,700. 11.54% of the stock is owned by corporate insiders.
BHC has been the topic of several analyst reports. BMO Capital Markets raised their target price on Bausch Health Companies from $20.00 to $22.00 and gave the stock a “market perform” rating in a report on Monday, August 13th. HC Wainwright reaffirmed a “hold” rating and set a $20.00 target price on shares of Bausch Health Companies in a report on Friday, August 31st. ValuEngine lowered Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 target price on shares of Bausch Health Companies in a report on Wednesday, September 12th. Finally, Deutsche Bank set a $30.00 target price on Bausch Health Companies and gave the stock a “buy” rating in a report on Wednesday, September 12th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $28.18.
ILLEGAL ACTIVITY NOTICE: This article was reported by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://baseballnewssource.com/2018/12/08/gsa-capital-partners-llp-invests-1-36-million-in-bausch-health-companies-inc-bhc-stock/3064367.html.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
See Also: What are retained earnings?
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.